An Overview of COVID-19 Vaccine Safety and Post-marketing Surveillance Systems

  • Manal Mohammed Younus Iraqi Pharmacovigilance Center, Ministry of Health, Iraq
  • Ali Azeez Al-Jumaili University of Baghdad College of Pharmacy, Baghdad, Iraq

Abstract

The need for the safety monitoring of the COVID-19 vaccine is unprecedented. It is an ongoing process starting from different phases of clinical trials and continued to post-marketing to tackle the emergency used authorized COVID-19 vaccines across the world. Rapid detection, exchange, prioritization, and assessment of safety signals based on available real-world data, surveillance of Adverse events following immunization (AEFI), and adverse event of special interest (AESI) by studying the observed/expected cases. Enhanced collaboration, and availability of resources, tools, and methods will add to the lessons learned from previous experiences.

article type

Letter

Downloads

Download data is not yet available.
Dates
Received 2021-08-01
Published 2021-10-12
Section
Pharmacy Practice & Practice-Based Research